CHRNA2 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q15822 |
---|---|
Clone Names | 101008079 |
Gene ID | 1135 |
---|---|
Other Names | Neuronal acetylcholine receptor subunit alpha-2, CHRNA2 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CHRNA2 |
---|---|
Function | After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. |
Cellular Location | Postsynaptic cell membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Nicotinic acetylcholine receptors (nAChRs) areligand-gated ion channels formed by a pentameric arrangement ofalpha and beta subunits to create distinct muscle and neuronalreceptors. Neuronal receptors are found throughout the peripheraland central nervous system where they are involved in fast synaptictransmission. This gene encodes an alpha subunit that is widelyexpressed in the brain. The proposed structure for nAChR subunitsis a conserved N-terminal extracellular domain followed by threeconserved transmembrane domains, a variable cytoplasmic loop, afourth conserved transmembrane domain, and a short C-terminalextracellular region. Mutations in this gene cause autosomaldominant nocturnal frontal lobe epilepsy type 4. Single nucleotidepolymorphisms (SNPs) in this gene have been associated withnicotine dependence.
References
Saccone, N.L., et al. Genes Brain Behav. 9(7):741-750(2010)Joslyn, G., et al. Alcohol. Clin. Exp. Res. 34(5):800-812(2010)Rigbi, A., et al. Pharmacogenomics J. (2010) In press :Hoda, J.C., et al. FEBS Lett. 583(10):1599-1604(2009)Philibert, R.A., et al. Nicotine Tob. Res. 11(3):286-292(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.